NASDAQ: BLTEBelite Bio Inc Stock
$159.16+4.66 (+3.02%)
Updated Apr 30, 2026
BLTE Price
$159.16
Fair Value Price
$10.51
Market Cap
$6.26B
52 Week Low
$56.10
52 Week High
$200.00
P/E
-68.9x
P/B
8.13x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$77.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.01
Operating Cash Flow
-$37M
Beta
0.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLTE Overview
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The company's pipeline of therapies is built on its RBP4 (Retinol Binding Protein 4) IP portfolio. Belite Bio is focused on meeting the unmet needs of patients suffering from blindness, liver disease, and diabetes. The company operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio was founded in 2016 and is based in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLTE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important BLTE news, forecast changes, insider trades & much more!
BLTE News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLTE ($159.16) is overvalued by 1,414.29% relative to our estimate of its Fair Value price of $10.51 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BLTE ($159.16) is not significantly undervalued (1,414.29%) relative to our estimate of its Fair Value price of $10.51 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BLTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BLTE due diligence checks available for Premium users.
Valuation
BLTE fair value
Fair Value of BLTE stock based on Discounted Cash Flow (DCF)
Price
$159.16
Fair Value
$10.51
Overvalued by
1,414.29%
BLTE ($159.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BLTE ($159.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BLTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BLTE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-68.9x
Industry
19.25x
Market
18.99x
BLTE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.13x
Industry
4.87x
BLTE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLTE's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.3M
Profit Margin
0%
BLTE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$780.6M
Liabilities
$10.1M
Debt to equity
0.01
BLTE's short-term assets ($494.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLTE's short-term assets ($494.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLTE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.4M
Investing
-$303.7M
Financing
$510.1M
BLTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLTE vs Biotech Stocks
Belite Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.